Taisho Pharmaceutical Holdings

Taisho Pharmaceutical Holdings is a prominent manufacturer of specialty and generic drugs, primarily focused on the production and sale of self-medication products. The company's portfolio includes a variety of well-known items, such as cold medicines, allergy medications, and dietary supplements like the Lipovitan and Pabron series. Operating through two main segments—Self-Medication and Prescription Pharmaceuticals—Taisho derives the majority of its revenue from the Self-Medication segment, catering primarily to external customers in Japan. The company also explores mergers and acquisitions as a strategy to enhance its research, development, manufacturing, and marketing capabilities.

Akira Uehara

Chairman, President and CEO

Past deals in Wearables

Biolinq

Series C in 2025
Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors for health monitoring. Founded in 2012, Biolinq focuses on creating a digital health platform that offers minimally invasive electrochemical biosensors. These sensors analyze biomarkers in interstitial fluid to deliver actionable health information, particularly for diabetic patients who need to monitor their blood glucose levels. By enabling continuous monitoring of multiple biomarkers, the company's technology aims to improve metabolic health and provide a more convenient alternative to traditional blood glucose monitoring methods.

Biolinq

Venture Round in 2024
Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors for health monitoring. Founded in 2012, Biolinq focuses on creating a digital health platform that offers minimally invasive electrochemical biosensors. These sensors analyze biomarkers in interstitial fluid to deliver actionable health information, particularly for diabetic patients who need to monitor their blood glucose levels. By enabling continuous monitoring of multiple biomarkers, the company's technology aims to improve metabolic health and provide a more convenient alternative to traditional blood glucose monitoring methods.

VIE STYLE

Series A in 2024
VIE STYLE offers wearable music device and AI technology services.

Biolinq

Series B in 2021
Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors for health monitoring. Founded in 2012, Biolinq focuses on creating a digital health platform that offers minimally invasive electrochemical biosensors. These sensors analyze biomarkers in interstitial fluid to deliver actionable health information, particularly for diabetic patients who need to monitor their blood glucose levels. By enabling continuous monitoring of multiple biomarkers, the company's technology aims to improve metabolic health and provide a more convenient alternative to traditional blood glucose monitoring methods.

Quantum Operation

Corporate Round in 2020
Quantum Operation, Inc. is a Tokyo-based company founded in 2017 that specializes in the development of innovative IoT wearable devices, particularly for blood sugar level management. The company focuses on creating smart watches designed to enhance diabetes management by minimizing the need for painful needle sticks. In addition to its healthcare technology, Quantum Operation also develops speech recognition systems, digital signage solutions, and AI surveillance cameras. Furthermore, the company provides IoT consulting services and engages in YouTuber movie production, showcasing its diverse capabilities within the technology sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.